These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 39191617)

  • 1. Impact of DPP4 Inhibition on Survival in Patients With Metastatic Renal Cell Carcinoma and Type 2 Diabetes Mellitus.
    Ali S; Fortune K; Masur J; Viscuse PV; Devitt ME; Dreicer R; Skelton WP
    Clin Genitourin Cancer; 2024 Oct; 22(5):102173. PubMed ID: 39191617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
    McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD
    Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
    Chang CY; Yeh YH; Chan YH; Liu JR; Chang SH; Lee HF; Wu LS; Yen KC; Kuo CT; See LC
    Cardiovasc Diabetol; 2017 Dec; 16(1):159. PubMed ID: 29258504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study.
    Guo JY; Chen HH; Yang YC; Wu PY; Chang MP; Chen CC
    J Diabetes Complications; 2020 Mar; 34(3):107515. PubMed ID: 31932172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes.
    Zhou J; Liu X; Chou OH; Li L; Lee S; Wong WT; Zhang Q; Chang C; Liu T; Tse G; Jing F; Cheung BMY
    Rheumatology (Oxford); 2023 Apr; 62(4):1501-1510. PubMed ID: 36066415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma.
    Izzedine H; Derosa L; Le Teuff G; Albiges L; Escudier B
    Ann Oncol; 2015 Jun; 26(6):1128-1133. PubMed ID: 25795198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of DPP4 inhibitors on the levels of plasma catecholamines and their metabolites in patients with type 2 diabetes.
    Kim TH; Lee K; Park IB; Choi CS; Ahn TH; Lee DH
    Diabetes Res Clin Pract; 2019 Oct; 156():107832. PubMed ID: 31513823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl peptidase-4 inhibitors reduced long-term cardiovascular risk in diabetic patients after percutaneous coronary intervention via insulin-like growth factor-1 axis.
    Chikata Y; Iwata H; Miyosawa K; Koike T; Yasuda H; Funamizu T; Doi S; Endo H; Wada H; Naito R; Ogita M; Dohi T; Kasai T; Isoda K; Okazaki S; Miyauchi K; Minamino T
    Sci Rep; 2022 Mar; 12(1):5129. PubMed ID: 35332212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower Risks of New-Onset Hepatocellular Carcinoma in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors Versus DPP4 Inhibitors.
    Chou OHI; Ning J; Chan RNC; Chung CT; Huang H; Ng K; Dee EC; Lee S; Kaewdech A; Chow AKM; Man NK; Liu T; Jing F; Cheung BMY; Tse G; Zhou J
    J Natl Compr Canc Netw; 2024 Jun; 22(2 D):. PubMed ID: 38862004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
    Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
    Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes.
    Na Y; Kim SW; Park IB; Choi SJ; Nam S; Jung J; Lee DH
    J Clin Endocrinol Metab; 2022 Nov; 107(11):3022-3034. PubMed ID: 36108097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease.
    Kornelius E; Huang CN; Lo SC; Wang YH; Yang YS
    Endocr Pract; 2020 Dec; 26(12):1486-1496. PubMed ID: 33471741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy for metastatic renal cell carcinoma.
    Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis.
    Min SH; Yoon JH; Moon SJ; Hahn S; Cho YM
    Sci Rep; 2018 Mar; 8(1):4466. PubMed ID: 29535389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of DPP4 and DPP4i in Glucose Homeostasis and Cardiorenal Syndrome.
    Panda SP
    Endocr Metab Immune Disord Drug Targets; 2023; 23(2):179-187. PubMed ID: 35642117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib.
    Keizman D; Gottfried M; Ish-Shalom M; Maimon N; Peer A; Neumann A; Hammers H; Eisenberger MA; Sinibaldi V; Pili R; Hayat H; Kovel S; Sella A; Boursi B; Weitzen R; Mermershtain W; Rouvinov K; Berger R; Carducci MA
    Oncologist; 2014 Jan; 19(1):51-60. PubMed ID: 24309979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
    Dombrowski S; Kostev K; Jacob L
    Osteoporos Int; 2017 Aug; 28(8):2421-2428. PubMed ID: 28455750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies.
    Sawaya GB; Dragomir A; Wood LA; Kollmannsberger C; Basappa NS; Kapoor A; Soulières D; Finelli A; Heng DYC; Castonguay V; Canil C; Winquist E; Graham J; Bjarnason GA; Bhindi B; Lalani AK; Pouliot F; Breau RH; Saleh R; Tanguay S
    Eur Urol Oncol; 2024 Jun; 7(3):570-580. PubMed ID: 38097481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.